Original Article
MicroRNA-223-3p functions as a tumor suppressor by regulating cell cycle in hepatocellular carcinoma

Lei Chen[1*], Fuxiang Yu[2*], Xun Cai[3], Jianxin Zhang[3], Xiong Cai[3], Dangdang Ma[3], Tan Fu[3], Maiyu Xu[1], Zhengping Yu[2], Gang Chen[2], Weidong Jin[3]

[1]Department of Hepatobiliary Surgery, Wenzhou Central Hospital, Wenzhou 325000, China; [2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China; [3]Department of General Surgery, Wuhan General Hospital of Guangzhou Military, Wuhan 430000, China. *Equal contributors.

Abstract: Increasing evidence displays that miRNA plays a significant role in the development and progression of cancer. In our previously study, we found that down-regulation of RPS15A could inhibit the proliferation of hepatocellular carcinoma (HCC) cell. However, comprehensive mechanisms of RPS15A in HCC development are still uncertain. In this study, we found that the expression levels of miR-223-3p were significantly reduced in HCC cell lines and clinical tissues. Meanwhile, we confirmed that ectopic expression of miR-223-3p could dramatically inhibit cell proliferation and promote cell apoptosis in HCC cells. Luciferase assay together with western blot assay established that miR-223-3p bound directly to the 3'-untranslated region (3'-UTR) of RPS15A and decreased the expression of RPS15A. Additionally, cyclinA, cyclinD1 and p21, the cell cycle related-genes, were also down-regulated when augmented the expression of miR-223-3p, which is similar as silencing RPS15A expression. Furthermore, co-transfection of miR-223-3p mimics with 3'UTR-deleted RPS15A could rescue the expressions of cyclinA and cyclinD1 while reduce the p21 expression. In summary, miR-223-3p functions as a novel tumor suppressor in HCC by regulating cell growth and cell cycle via binding to RPS15A 3'UTR. These findings may be employed in developing novel therapeutic approaches for HCC treatment.

Keywords: Hepatocellular carcinoma, miR-223-3p, RPS15A, cell cycle

Introduction

Primary liver cancer is the sixth most common cancer in the world and the third most common cause of cancer mortality. There is wide geographic variability in incidence with a majority of the cases occurring in developing countries. And hepatocellular carcinoma (HCC) accounting for approximately 85% of all primary liver cancers [1]. The major factors for HCC include alcoholic liver disease, nonalcoholic fatty liver disease, cirrhosis, and especially hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. In China, there are more than 93 million HBsAg-positive subjects, of whom about 20 million have chronic HBV infection [2]. The hepatic B virus x protein (HBxAg) plays an important role in the development of HCC. Evidence showed that HBxAg promote hepatic cells proliferation partly through the upregulated expression of ribosomal protein s15a (RPS15A). In our previ-

ously study, we also found that down-regulation of RPS15A could inhibit the proliferation of human hepatic cancer cell in vitro [3]. However, detailed mechanisms of RPS15A in HCC development are still unclear.

MicroRNAs (miRNAs) function at the posttranscriptional level by negatively regulating translation of their target mRNAs by imperfect binding to their 3'UTRs. miRNAs have emerged as key regulators of diverse physiological and pathological processes, including cell proliferation, apoptosis, and cancer. Several recent researches showed miRNA played a very important role in HCC progression such as miR-101 [4], miR-224 [5, 6] promoted cell apoptosis, while miR-122a [7], miR-195 [8], miR-31 [9] suppressed HCC through regulate cell cycle, down regulated miR-152 [10] induced aberrant DNA methylation in HCC.

In addition, several research groups were showed miR-223-3p inhibit HCC progression through different pathway. Wang CM [11] and Bae HJ [12] have showed miR-223-3p functions as a tumor suppresser by targeting TNFAIP3 and SIRT1 respectively. Whereas, Yujuan Xiong found miR-223-3p was HCC suppressor and promoted cell apoptosis by Bcl-2 and Mcl-1 through mitochondrial pathway [13]. But, miR-223-3p functions in inhibit HCC growth might have other pathway. In this study, we showed that miR-223-3p expression was obviously reduced in HCC tissues and cell lines. Ectopic expression of miR-223-3p could inhibit HCC cell lines growth and induce apoptosis. We also found that miR-223-3p could regulate the expression of cell cycle related protein through down-regulate RPS15A. Our study revealed that miR-223-3p acts as a tumor suppressor by interacting with RPS15A mRNA.

Materials and methods

Clinical samples

We obtained 5 human hepatic para-carcinoma tissue samples and 10 hepatic cancer tissue samples from newly diagnosed HCC patients in Wuhan General Hospital of Guangzhou Military. All patients gave informed consent and use of the samples for molecular studies.

Cell lines, cell culture and transfection

Hepatic cancer cell lines HepG2, and Hep3B were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Hepatic cancer cell lines Bel7404, SMMC-7721, the liver cell line LO2 and human embryonic kidney cell line 293T were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). All cell lines were maintained in DMEM (dulbecco's modified eagle medium), supplemented with 10% fetal bovine serum and 100 U/mL penicillin, 100 mg/mL streptomycin, cultured at 5% CO_2 and humidified 37°C chamber (Thermo Fisher). All cell culture related reagents were purchased from Gibco.

Harvest all the cells and seed 5×10^5 cells per well of six-well plate. After 18 h, mix 5 µL scramble, miRNA mimics or inhibitor (20 µM), 91 µL RNase-free water and 4 µl X-tremeGENE HP DNA transfection reagent (Roche, Indianapolis, IN, USA). After 20 min, pour the mix into a well of six-well plate and cultured in cell culture chamber. And the sequence of all the miRNA and siRNA were as follows: NC: 5'-TTCTCCG-AACGTGTCACGT-3'; RPS15A siRNA: 5'-CATGG-TTACATTGGCGAATT-3'. SiRNA was synthesized by Genepharma (Shanghai, China). miRNA mimics scramble: 5'-UUCUCCGAACGUGUCACGU-TT-3'; miRNA inhibitor scramble: 5'-CAGUACU-UUUGUGUAGUACAA-3'. miR-223-3p mimics, inhibitors were purchased from genecopoeia (Guangzhou, China).

MTT proliferation assay

To detect cell viability, MTT colorimetric assay was performed 1 day after transfection. All the cell lines were washed with phosphate-buffered saline (PBS) and digested by trypsin, seeded 2000 cells per well in 96-well plate. The plate was incubated for 1 to 5 days in 37°C and 5% CO_2 humidified chamber. 50 µL of MTT (10 mg/mL) were added and incubated for 2 h at 37°C, discarded the MTT and 100 µL Dimethyl Sulphoxide (DMSO, D8418, Sigma) was added to each well. The absorbance at 595 nm was measured using microplate reader (Bio Tek Instruments, Winooski, VT, USA).

Cell colony forming assay

Pour 1×10^3 cells per well in six-well plate on day after miRNA mimics or inhibitor transfection. The medium was changed every 3 days. After 14 days of culture at 37°C, discarded the medium, washed with PBS. Poured 4% paraformaldehyde to fix the cell for 10 min at room temperature, stained with crystal violet for 10 min at room temperature, washed with water and dried in baking oven at 55°C. Cell survival was counted according to the usual criterion of 50 cells or more per colony.

Flow cytometric analysis

Cell cycle and percentage of apoptotic cells were assessed by FACScalibur flow cytometry (Becton Dickinson, San Jose, CA, USA). Samples for cell cycle were harvested by trypsin and fixed by 70% ethanol in PBS in -20°C overnight, washed twice with PBS and stained by propidium iodide (PI) with RNase (550825, Becton Dickinson, San Diego, CA, USA) for 30 min in dark. Fluorescent emissions were collected through FL2 band-pass filter. Samples for apoptosis were collected by trypsin without EDTA, washed twice with PBS, stained by 5 µL PI and 5 µL FITC-Annexin V in 100 µL binding buffer for

15 min in dark (BMS500FI, ebioscience, Belgium). Fluorescent emissions were collected through FL1 band-pass filter for FITC-Annexin V, FL2 for PI. The apoptotic were PI and FITC-Annexin V both positive cells.

Protein extraction and western blot

Cells were lysed in RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF and protease inhibitor cocktail) for 30 min on ice, protein quantificated with BCA protein assay kit (Beyotime, Shanghai, China), and 1/5 volumes of 5× SDS-loading buffer (250 mM Tris-HCl (pH 6.8), 10% SDS, 0.5% bromophenol blue, 50% glycerol, 5% β-mercaptoethanol) were added to denaturing the protein. Equal amounts of protein were separated by SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). The blots were blocked with 5% BSA (Albumin from bovine serum, Beyotime, Shanghai, China) and incubated with indicated antibodies. The Immobilon Western blot detection system (Millipore, Billerica, MA) was used to detect bound antibodies. Antibodies used in the experiment: RPS15A (sc-162101, Santa Cruz, USA), CyclinA (ab38, Abcam, Cambridge, MA), CyclinD1 (ab134175, Abcam, Cambridge, MA), CyclinE (ab93161, Abcam, Cambridge, MA), p21 (2947, cell signaling, Beverly, MA), beta-actin (sc-47778, Santa Cruz, USA), Flag (ab1162, Abcam, Cambridge, MA), goat anti-mouse IgG HRP (m21001, Abmart, Shanghai, China), goat anti-rabbit IgG HRP (m21002, Abmart, Shanghai, China).

RNA extraction and quantitative real-time PCR

Total RNA was isolated from cells or human tissue samples by using TRIzol reagent (Invitrogen, Carlsbad, CA). miR-223-3p: the first-strand complementary miRNA was synthesized using the specific RT primer from total RNA using TaqMan MicroRNA Reverse Transcription Kit. miR-223-3p expression were evaluated by real-time PCR using indicated taqman probes and TaqMan® Universal PCR Master Mix II on an ABIPRISM 7500 Real-time PCR system. And the expression level of U6 snRNA was used as the loading control. Relative mRNA was determined by using the formula $2^{-\Delta CT}$ (CT, cycle threshold) where $\Delta CT = CT$ (target miRNA) - CT (U6). Human miR-223-3p and U6 RT primers, TaqMan MicroRNA Reverse Transcription Kit, miR-223-3p and U6 Taqman probes, TaqMan®

Universal PCR Master Mix II, no UNG were all purchased from Applied systems (fostercity, CA). All procedures were carried out according manufacture's instrument. RPS15A: the first-strand complementary miRNA was synthesized using oligo dT from total RNA using the PrimeScript RT master Mix Perfect Real Time (Takara, Dalian, China). RPS15A mRNA expression level was detected by real time PCR using SYBR green (Takara, Dalian, China) on ABI-PRISM 7500 real time PCR system. GAPDH served as loading control. The primers of RPS-15A as described before [3] and GAPDH primers [14] were: Forward, 5'-GGTGTGAACCATGA-GAAGTATGA-3'; Reverse, 5'-GAGTCCTTCCACGA-TACCAAAG-3'.

*Plasmids construction and luciferase reporter assay*

pME18s-RP15A: RPS15A coding sequence (CDS) cloned into pME18s plasmid; pME18s-RP15A-3'UTR: RPS15A CDS and 3'UTR (position 1-3000 bp) cloned into pME18s plasmid; pME18s-RPS15A-FLAG: RPS15A CDS and flag tag 5 times repeats cloned into pME18s plasmid. pGL3-RP15A-3'UTR: RP15A-3'UTR position 1000-3000 bp cloned into pGL3 firefly luciferase expression plasmid; pGL3-RP15A-3'UTR-mut: pGL3-RP15A-3'UTR position 1831-1837 mutation. Together with pRL-TK Renilla luciferase report plasmid, all of the plasmids were cloned by Genecopoeia (Guangzhou, China).

Luciferase reporter assay

293T, HepG2, Bel7404 were seeded onto 24-well plate a day before transfection, 1×10^5 cells per well. Cells were co-transfected with pGL3 firefly luciferase plasmid and miR-223-3p mimic or inhibitor separately by X-treme GENE HP DNA transfection reagent (Roche, Indianapolis, IN, USA), pRL-TK Renilla luciferase report plasmid was used as internal loading control. After transfection 48 h, poured 100 μL Passive Lysis Buffer to lysis cell and luciferase activities were measured by using the Dual-Luciferase reporter assay system (E1910, Promega).

Biotin-labelled RNA pull down assay

HepG2 and Bel7404 cells were transfected with Bio-miR-223-3p or Bio-miR-control in two 60 mm dishes. After 48 hours of incubation, the cells were trypsinized and washed twice

Figure 1. Reduced levels of miR-223-3p expression in HCC cell lines and tissues. A. Real-time PCR analysis of miR-223-3p expression in 5 nonneoplastic liver specimens and 10 human HCC tissues. The average miR-223-3p expression was normalized by U6 expression. Data are shown as means ± SD; n = 3, *P < 0.05 by ANOVA compared to 5 nonneoplastic liver specimens. B. Real-time PCR analysis of miR-223-3p expression in normal human liver cell and various tumor cell lines. Data are shown as means ± SD; n = 3, *P < 0.05 by ANOVA compared to LO2. C. Western blotting analysis of RPS15A in normal human liver cell and HCC cell lines, β-actin served as the loading control. Data are shown as means ± SD; n = 3, *P < 0.05 by ANOVA compared to LO2.

of lysis buffer with DNaseI (2 U/μL) was added. After incubation at 37°C for 10 min, lysates were centrifuged at 5,000 g for 5 min and the supernatant was discarded. Protein kinase K (20 mg/mL) and 1 μL of 10% SDS in 100 μL of lysis buffer were added to the pellet and incubated at 55°C for 20 min. RNA bound to the beads (pull-down RNA) or from 10% of the extract (input RNA), was isolated with Trizol reagent (Invitrogen). The levels of RPS15A in the Bio-miR-223-3p pull-down were quantified by qRT-PCR. GAP-DH was used for normalization.

Statistical analysis

The results were determined as mean ± SD of three independent experiments, in which each assay was performed in triplicate. *P*-values calculated by student's t test or ANOVA using SPSS 14.0 software and *P* < 0.05 were considered statistically significant.

Results

Reduced levels of miR-223-3p expression in HCC cell lines and tissues

To investigate the miR-223-3p expression level in HCC and normal tissue, we obtained 5 hepatic para-carcinoma tissues and 11 HCC tissues from newly diagnosed patients. Real-time PCR was conducted to measure the mRNA level of miR-223-3p. We found miR-223-3p levels were much lower in HCC tissues as compared with para-carcinoma tissues (**Figure 1A**). Furthermore, significant down-regulation of miR-223-3p were also found in HCC cell lines compared with LO2 cell (**Figure 1B**). RPS15A was decreased in HCC and played important role in HCC growth, as described before, down-regula-

with PBS. Cells were resuspended in 0.7 mL of lysis buffer (20 mM Tris (pH 7.5), 100 mM KCl, 5 mM $MgCl_2$, 0.3% IGEPAL CA-630) and then incubated on ice for 20 min. The cytoplasmic lysate was isolated by centrifugation at 10,000× for 15 min and supernatant was collected. The lysate was added to the Strepatavidin-coated magnetic beads (Invitrogen) and incubated and incubated overnight at 4°C. The beads were washed with lysis buffer for 5 times and 100 μL

Figure 2. miR-223-3p inhibits the growth of HCC cell in vitro. A. Ectopic expression of miR-223-3p suppressed HepG2 cell proliferation. The cell viability was determined by measuring MTT absorbance at A570. Cell growth was measured at every 24 hours. NC represents negative control microRNA. Data are shown as means ± SD; *n* = 3, *P

< 0.05 by ANOVA compared to NC. B. Representative micrographs of crystal violet stained cell colonies. Representative quantification of crystal violet stained cell colonies. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA. C. After transfection of miR-223-3p mimics or inhibitor to HepG2, the DNA content of PI-stained cells was analyzed by flow-cytometry. Cells staining positive for FITC-Annexin V and negative for PI at 48 h post-transfection were considered to have undergone apoptosis. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA. D. Representative images depicting the invasion ability of HepG2 after scramble control, or miR-223-3p mimics 48 h transfection.

tion of RPS15A inhibit HCC growth in HCC cell lines. Therefore, we validated the RPS15A protein level in LO2 and HCC cell lines and found greatly reduction in LO2 (**Figure 1C**).

*MiR-223-3p inhibits the growth of HCC cell line in vitro*

To explore the role of miR-223-3p down-regulation in the development and progression of HCC, we generated miR-223-3p-mimic and miR-223-3p-inhibitor respectively. Transfected with miR-223-3p-mimic and miR-223-3p-inhibitor and negative control microRNA, we tried to reveal the gain-of-function effect or lose-of-function effect on the proliferation of the HepG2 cell line. Results from the MTT (Methyl thiazolyltetrazolium) assay indicated that miR-223-3p up-regulation significantly inhibited the proliferation rate of HepG2 cells compared with the control while this situation would be rescued by the miR-223-3p suppression when cells were transfected by miR-223-3p-inhibitor (**Figure 2A**). Results of crystal violet stained of cell colonies showed obvious reduction of cell proliferation in miR-223-3p overexpression cell line (**Figure 2B**). Same results were obtained from three independent repeats. In addition, the colony formation assays showed that the HepG2 cell was significantly increased in response to miR-223-3p inhibitor (**Figure 2B**). Furthermore, these results suggested that miR-223-3p up-regulation inhibits hepatic cell tumorigenicity in vitro. This result was further confirmed by FACS analysis, which showed decreased the percentage of cells in S phase and increased the percentage of cells in G0/G1 phase in miR-223-3p-overexpressing cell and at the same time we found that transfection of the miR-223-3p-inhibitor drastically increased the percentage of cells in the S peak but decreased the percentage of cells in the G0/G1 peak (**Figure 2D**). Double staining of the infected HepG2 cell with Annexin V-FITC and PI showed an obvious raise ratio of apoptosis in miR-223-3p-overexpressing cell compared with the control cell while transfected with miR-

223-3p-inhibitor can also rescue the apoptotic rate of HepG2 cell. Taken together, these results indicate that miR-223-3p suppresses HCC cell proliferation and the proliferative effect of inhibiting miR-223-3p in HCC cells may occur through regulation of G1/S transition.

MiR-223-3p regulates RPS15A expression by binding 3'-UTR in HCC

Since miRNAs usually exert their function by negatively regulating the expression of their target genes and our results above indicate the tumor suppressive role of miR-223-3p in HCC, putative oncotargets of miR-223-3p were predicted using target prediction programs, TargetScan (http://www.targetscan.org/) and miRanda (http://www.microrna.org/microrna/). Our analysis revealed that RPS15A was a potential target of miR-223-3p. The 3'-UTR of RPS15A messenger RNA contains a complementary site for the seed region of miR-223-3p (**Figure 3A**). Although our previously study showed RPS15A may modulate hepatic cancer growth and play a prominent role in heptocarcinogenesis, the interaction between miR-223-3p and RPS15A has not been experimentally validated in HCC. To determine whether RPS15A is direct target of miR-223-3p, wild-type and mutant 3'-UTR lacking miR-223-3p binding sites were cloned into the downstream of firefly luciferase coding region in pGL-3 luciferase reporter vector. The constructs were then co-transfected with miR-223-3p mimic or scramble pGL3-RPS15A-3'UTR or pGL3-RPS15-3'UTR-mut and pRL-TK renilla luciferase vector into human embryonic kidney cell line 293T, respectively. Firefly luciferase values were normalized to renilla luciferase activity. The relative luciferase activity was reduced by 50% in pGL-3 vectors with wild-type RPS15A 3'-UTR, but not in those with respective mutant 3'-UTRs (**Figure 3B**). In addition, the endogenous miR-223-3ps inhibited the luciferase activity of the pGL-3 vectors with wide-type RPS15A 3'-UTR but did not affect the luciferase activity of the pGL-3 vectors with mutant 3'-UTR (**Figure**

Figure 3. miR-223-3p regulates RPS15A expression by binding 3'-UTR in HCC. A. Schematic representation of RPS15A 3'-UTRs showing putative miR-223-3p target site. B. Relative luciferase activity of the indicated RPS15A reporter constructs in 293T cells. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA compared to NC. C. Luciferase activity assay with wild-type RPS15A 3'-UTRs constructs and mutated luciferase constructs in HepG2 and Bel7404 cells. Firefly luciferase values were normalized to Renilla luciferase activity and plotted as relative luciferase activity. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA. D. The Biotin-labeled miR-223-3p-mRNA pull down assay. HepG2 and Bel7404 cells were transfected with Biotin-labeled microRNA control (Bio-NC) or Biotin-labeled miR-223-3p mimics for 48 hours. The expressions of RPS15A were measured by qRT-PCR and normalized to GAPDH. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by t test compared to NC. E. Western blot analysis of RPS15A expression in HepG2 and Bel7404 cells transfected with scramble oligonucleotide or miRNA mimics/miRNA inhibitors. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by t test compared to NC.

3C) in HepG2 and Bel7404, suggesting that miR-223-3p cognate sites are essential for negative regulation of luciferase expression driven by RPS15A-3'-UTR. Consistent with this observations, the Biotin-labeled miR-223-3p-mRNA pull down assay results also showed obvious reduction of the amount of RPS15A protein in miR-223-3p-overexpressing both in HepG2 and Bel7404 cells (**Figure 3D**). To confirm that miR-223-3p can indeed suppress expression of endogenous RPS15A, HepG2 and Bel7404 cells were transfected with miR-223-3p or scramble mimics, followed by detection of their protein levels. The protein levels of RPS15A was substantially decreased after ectopic overexpression of miR-223-3p in HepG2 and Bel7404 cell lines as evidenced by western blot assays (**Figure 3D**). Opposite, knocking down of miR-223-3p by anti-miR-223-3p in HepG2 and Bel7404 cells increased protein levels of RPS15A (**Figure 3D**). Taken together, these findings indicate that RPS15A can be negatively regulated by miR-223-3p in HCC cells.

Figure 4. miR-223-3p inhibits cell proliferation through targeting RPS15A 3'UTR and regulating cell cycle related molecules in HCC. A. Representative micrographs of crystal violet stained cell colonies. B. Representative quantification of crystal violet stained cell colonies. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA. C. HepG2 cell were transfected with miR-223-3p mimics or inhibitor. si-RPS15A were used for knockdown of miR-223-3p target genes, respectively. The protein expression levels of G1/S regulatory molecules were analyzed by immunoblotting. NC represents negative control miRNA. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA. D. Co-transfection of miR-223-3p with 3'UTR-deleted RPS15A plasmid (pME18s-RPS15A-FLAG) rescued the expressions of G1/S regulatory molecules. The expressions were analyzed by immunoblotting. Data are shown as means ± SD; $n = 3$, *$P < 0.05$ by ANOVA.

MiR-223-3p inhibits cell proliferation through targeting RPS15A 3'UTR and regulating cell cycle related molecules in HCC

To investigate whether miR-223-3p inhibits cell proliferation was implicated with regulation of RPS15A, RPS15A and RPS15A 3'UTR were respectively transfected into HepG2 cell with miR-223-3p mimics using the X-treme GENE HP DNA transfection reagent. The result of colony formation assay showed overexpressing RPS-15A significantly increased the proliferation rate of HepG2 cell compared with that cells expressing RPS15A 3'UTR (**Figure 4A**) and similar results were obtained from 3 independent repeats (**Figure 4B**). The rescuing experiment further confirmed that the inhibitory role of miR-223-3p in HCC cell may be mediated by RPS-15A. Our data showed that miR-223-3p exerts tumor suppressor function by regulating cell proliferation in HCC. Therefore, we examined some cell cycle regulator. Such as cyclinA, cyclinD1, cyclinE and p21, which has been

implicated in the control of the G1 to S phase transition in mammals. Interestingly, we found the protein level of cyclinA and cyclinD1, a CDK regulator important for regulating the G1/S transition, was down-regulated in HepG2 cell transfected with miR-223-3p-mimics, which is similar as transfected the si-RPS15A, but increased in the cells transfected with miR-223-3p-inhibitor, compared with control cells (**Figure 4C**). On the other hand, the expression of p21 was increased in miR-223-3p overexpressing cells and inhibited in the miR-223-3p inhibited cells but the protein level of cyclinE was not affected obviously (**Figure 4C**). Co-transfection of miR-223-3p with 3'UTR-deleted RPS15A rescued the expressions of cyclinA and cyclinD1 while down-regulating the p21 expression (**Figure 4D**).

Discussion

It is well known that miRNAs play important roles in tumorigenesis of various human can-

cers, including hepatocellular cancer [14]. Recent evidence has shown that miR-223-3p might exert extensive effects in the development and growth of human cancer [15]. It has also been identified that miR-223-3p were significantly down-regulated in multiple cancers including lung cancer [16], acute or chronic myeloid leukemia [17, 18], nasopharyngeal cancer [19] and hepatocellular carcinoma [20]. Herein, we also found that miR-223-3p was down-regulated in HCC tissues and cell lines. Moreover, we demonstrated that up-regulation of miR-223-3p suppressed the growth and invasion of hepatocellular carcinoma cells, suggesting that miR-223-3p may function as a tumor suppressor in HCC.

Previous studies have reported that miR-223-3pc significantly inhibits the proliferation of squamous cell carcinoma cell and induces cell apoptosis [21]. Consistent with previous studies, our MTT assay and FACs analysis showed that overexpression of miR-223-3p inhibits the proliferation of hepatocellular carcinoma and promotes apoptosis. Nevertheless, the biological function and underling mechanisms of miR-223-3p in HCC are largely unknown.

To address the molecular mechanisms involved in miR-223-3p in inhibition of proliferation and invasion, we searched for potential target genes with an established or potential function in HCC. Interestingly, a perfect match between the miR-223-3p seed region and the 3'UTR of RPS15A was identified. RPS15A gene, which encodes a ribosomal protein, is a component of the 40S ribosomal subunit. Emerging evidence has shown that RPS15A correlate with the development and progression of various cancers [22-24]. Our previous study also demonstrated down-regulation of RPS15A inhibits proliferation of HCC and regulates cell cycle progress. In our current study, our data firstly show that miR-223-3p interacts with RPS15A by directly binding RPS15A 3'UTR. Our luciferase reporter assay and western blotting analysis consistently confirmed that the protein level of RPS15A is upregulated in HCC cells and negatively correlated with miR-223-3p expression.

Our data showed the defect in G1/S phase transition in miR-223-3p-overexpressing cells (**Figure 2C**). Then we examined the expression of several cell cycle regulator molecules which are reported to be important for regulating the G1/S transition. The results showed that the important molecules in the regulation at G1/S transition, such as cyclinA and cyclinD1, were significantly down-regulated while p21 was up-regulated in miR-223-3p-overexpressing cells.

Taken together, our analysis revealed that the expression of miR-223-3p was decreased in HCC and miR-223-3p inhibited HCC proliferation and cell cycle progression via directly suppressing RPS15A expression. Targeting to the miR-223-3p/RPS15A interaction or rescuing miR-223-3p expression may be a new therapeutic application to treat hepatocellular carcinoma patients in the future.

Disclosure of conflict of interest

None.

Address correspondence to: Weidong Jin, Department of General Surgery, Wuhan General Hospital of PLA, 627 Wuluo Road, Wuhan 430000, China. Tel: +86-27-50773333; Fax: 86-27-50773366; E-mail: jwdong1972@126.com; Gang Chen, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang, Ouhai District, Wenzhou 325000, China. Tel: 86-577-55579453; Fax: 86-577-55579555; E-mail: chen.gang@wmu.edu.cn

References

[1] Herszenyi L and Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 2010; 14: 249-258.

[2] Lu FM and Zhuang H. Management of hepatitis B in China. Chin Med J (Engl) 2009; 122: 3-4.

[3] Xu M, Wang Y, Chen L, Pan B, Chen F, Fang Y, Yu Z and Chen G. Down-regulation of ribosomal protein S15A mRNA with a short hairpin RNA inhibits human hepatic cancer cell growth in vitro. Gene 2014; 536: 84-89.

[4] Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y and Zhuang SM. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.

[5] Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H and Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 565-575.

[6] Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P and Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-13215.

[7] Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, Croce CM, Bolondi L and Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-6099.

[8] Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP and Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113-121.

[9] Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, Kang YK and Nam SW. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget 2015; 6: 8089-8102.

[10] Huang J, Wang Y, Guo Y and Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010; 52: 60-70.

[11] Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG and Jia JH. miR-223-3pc targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 2011; 411: 586-592.

[12] Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, Lee JY and Nam SW. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2014; 33: 2557-2567.

[13] Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845.

[14] Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303.

[15] Jiang H, Zhang G, Wu JH and Jiang CP. Diverse roles of miR-223-3p in cancer (review). Oncol Rep 2014; 31: 1509-1516.

[16] Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K and Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104: 15805-15810.

[17] Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M and Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331-5341.

[18] Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D and Lagneaux L. MicroRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113: 5237-5245.

[19] Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B and Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008; 105: 5874-5878.

[20] Zhu XC, Dong QZ, Zhang XF, Deng B, Jia HL, Ye QH, Qin LX and Wu XZ. MicroRNA-29a suppresses cell proliferation by targeting SPARC in hepatocellular carcinoma. Int J Mol Med 2012; 30: 1321-1326.

[21] Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J, Wang Z, Tan FW, Tan XG, Li BZ, Zhou F, Shao K, Li N, Qiu B and He J. MiR-223-3pc induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclinE expression. Carcinogenesis 2011; 32: 1025-1032.

[22] Zhao X, Shen L, Feng Y, Yu H, Wu X, Chang J, Shen X, Qiao J and Wang J. Decreased expression of RPS15A suppresses proliferation of lung cancer cells. Tumour Biol 2015; 36: 6733-40.

[23] Zhang C, Zhang T, Song E, Himaya SW, Chen X and Zheng L. Ribosomal protein S15A augments human osteosarcoma cell proliferation in vitro. Cancer Biother Radiopharm 2014; 29: 451-456.

[24] Daftuar L, Zhu Y, Jacq X and Prives C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One 2013; 8: e68667.